Nonstandardized Allergenic Products

Manufacturer
ALK-Abello, Inc.
Effective date
2026-11-06
Label type
NON-STANDARDIZED ALLERGENIC LABEL
Version
14
Source
daily-update
Hydrated at
2026-11-07 03:02:57

Label at a glance#

ProductPROSOPIS JULIFLORA POLLEN
Active ingredientPROSOPIS JULIFLORA POLLEN, ZEA MAYS POLLEN, CANIS LUPUS FAMILIARIS SKIN, CAVIA PORCELLUS SKIN, EQUUS CABALLUS SKIN, ACACIA, ALNUS INCANA SUBSP. RUGOSA POLLEN, MEDICAGO SATIVA POLLEN, FRAXINUS VELUTINA POLLEN, FRAXINUS AMERICANA POLLEN, PASPALUM NOTATUM POLLEN, MORELLA CERIFERA POLLEN, FAGUS GRANDIFOLIA POLLEN, BETULA LENTA POLLEN, BETULA NIGRA POLLEN, USTILAGO MAYDIS, BOS TAURUS SKIN, MUS MUSCULUS SKIN, RABBIT, PERIPLANETA AMERICANA, BLATTELLA GERMANICA, ACER NEGUNDO POLLEN, BROMUS INERMIS POLLEN, AMARANTHUS PALMERI POLLEN, JUNIPERUS ASHEI POLLEN, JUNIPERUS VIRGINIANA POLLEN, XANTHIUM STRUMARIUM VAR. CANADENSE POLLEN, TAXODIUM DISTICHUM POLLEN, RUMEX ACETOSELLA POLLEN, RUMEX CRISPUS POLLEN, EUPATORIUM CAPILLIFOLIUM POLLEN, ULMUS AMERICANA POLLEN, ULMUS CRASSIFOLIA POLLEN, ULMUS PUMILA POLLEN, EUCALYPTUS GLOBULUS POLLEN, SOLIDAGO CANADENSIS POLLEN, POPULUS DELTOIDES POLLEN, POPULUS DELTOIDES SUBSP. MONILIFERA POLLEN, CUPRESSUS ARIZONICA POLLEN, CELTIS OCCIDENTALIS POLLEN, SORGHUM HALEPENSE POLLEN, JUNIPERUS CALIFORNICA POLLEN, BASSIA SCOPARIA POLLEN, CHENOPODIUM ALBUM POLLEN, ACER RUBRUM POLLEN, ACER SACCHARUM POLLEN, CYCLACHAENA XANTHIFOLIA POLLEN, IVA ANNUA POLLEN, ARTEMISIA VULGARIS POLLEN, MORUS RUBRA POLLEN, MORUS ALBA POLLEN, QUERCUS RUBRA POLLEN, QUERCUS VIRGINIANA POLLEN, QUERCUS ALBA POLLEN, OLEA EUROPAEA POLLEN, SYAGRUS ROMANZOFFIANA POLLEN, CARYA ILLINOINENSIS POLLEN, SCHINUS MOLLE POLLEN, AMARANTHUS RETROFLEXUS POLLEN, AMARANTHUS SPINOSUS POLLEN, CASUARINA EQUISETIFOLIA POLLEN, PINUS STROBUS POLLEN, PINUS ECHINATA POLLEN, PLANTAGO LANCEOLATA POLLEN, POPULUS ALBA POLLEN, LIGUSTRUM VULGARE POLLEN, ELYMUS REPENS POLLEN, AMBROSIA ACANTHICARPA POLLEN, AMBROSIA ARTEMISIIFOLIA POLLEN, AMBROSIA TRIFIDA POLLEN, AMBROSIA PSILOSTACHYA POLLEN, SALSOLA KALI POLLEN, ARTEMISIA TRIDENTATA POLLEN, LIQUIDAMBAR STYRACIFLUA POLLEN, PLATANUS OCCIDENTALIS POLLEN, JUGLANS NIGRA POLLEN, AMARANTHUS TUBERCULATUS POLLEN, SALIX NIGRA POLLEN
Label structure15 sections

Boxed warning

This product is intended for use by physicians who are experienced in the administration of allergenic extracts and the emergency care of anaphylaxis or for use under the guidance of an allergy specialist. Patients should be instructed to recognize adverse reaction symptoms and cautioned to contact the physician’s office if reaction symptoms occur. As with all allergenic extracts, severe systemic reactions may occ...

Indications and uses

Hyposensitization (injection) therapy is a treatment for patients exhibiting allergic reactions to seasonal pollens, dust, molds, animal danders, various other inhalants, and in situations where the offending allergen cannot be avoided. Prior to initiation of therapy, the clinical sensitivity should be established by careful evaluation of the patient’s history confirmed by diagnostic skin testing. Hyposensitizatio...

Dosage and administration

Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. When diluting bulk extracts, use of Sterile Diluent for Allergenic Extracts or Sterile Diluent for Allergenic Extracts Normal Saline with HSA (albumin saline) is recommended. Dilutions should be made with sterile disposable syringes using aseptic technique....

Label contents#

Full prescribing information#

SPL UNCLASSIFIED SECTION

DIRECTIONS FOR USE OF

THERAPEUTIC ALLERGENIC EXTRACTS

WARNING

BOXED WARNING SECTION

This product is intended for use by physicians who are experienced in the administration of allergenic extracts and the emergency care of anaphylaxis or for use under the guidance of an allergy specialist.

Patients should be instructed to recognize adverse reaction symptoms and cautioned to contact the physician’s office if reaction symptoms occur. As with all allergenic extracts, severe systemic reactions may occur. In certain individuals, these reactions may rarely result in death. Patients should be observed for 20 to 30 minutes following treatment, and emergency measures, as well as personnel trained in their use, should be immediately available in the event of a life-threatening reaction. Patients with unstable asthma or steroid dependent asthmatics and patients with underlying cardiovascular disease are at greater risk. Adverse events are to be reported to Med Watch (1-800-FDA-1088), Adverse Event Reporting , Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20852-9787.

This product should not be injected intravenously. Deep subcutaneous routes have proven to be safe. Patients receiving beta-blockers may not be responsive to epinephrine or inhaled bronchodilators. Respiratory obstruction not responding to parenteral or inhaled bronchodilators may require theophylline, oxygen, intubation and the use of life support systems. Parenteral fluid and/or plasma expanders may be utilized for the treatment of shock. Adrenocorticosteroids may be administered parenterally or intravenously.

Refer to WARNINGS, PRECAUTIONS, and ADVERSE REACTIONS sections below.

SPL UNCLASSIFIED SECTION

Port Washington, NY 11050

U.S. Government License No. 1256

DESCRIPTION

DESCRIPTION SECTION

Sterile therapeutic extracts are supplied in either Phenol Saline Diluent or in Diluent containing Glycerin 50% (v/v) for subcutaneous injection. Inactive ingredients may include: Sodium Chloride for isotonicity, Glycerin, and Sodium Bicarbonate as buffering agents. These products are compounded and diluted on a w/v or PNU basis. Pollens are individually extracted from pure pollen extracted in a phenol-preserved sodium bicarbonate solution. Short Ragweed and Mixed (Tall and Short) Ragweed extracts are standardized by Antigen E content and so labeled. The Antigen E content of extracts containing Short Ragweed at a concentration more dilute than a weight/volume ratio of 1:10 are obtained by calculating the Antigen E content based on the assay value of more concentrated extract. Pollen extracts are filtered aseptically and, after final packaging, they are tested for sterility and safety. Molds are individually extracted from pure powdered inactivated mold source material extracted in phenol preserved saline. Mold extracts are filtered aseptically and after final packaging are tested for sterility and safety. Molds are present in all inhabited places at all seasons of the year; they are so ubiquitous that they are prevalent at times when common allergic pollens and other inhalants are not. In the home and surroundings, molds are found in upholstered furniture, mattresses, drapes, cellar and storage room dust, woolens, leather goods, fruits, meats, cheeses, garden soil and on plants. Spores, mycelial fragments and mold residues are thus inhaled, contacted and ingested continuously.

Miscellaneous inhalants and epidermals are individually extracted in phenol preserved saline, filtered aseptically and after final packaging are tested for sterility and safety.

CLINICAL PHARMACOLOGY

CLINICAL PHARMACOLOGY SECTION

The treatment consists of the subcutaneous injection of gradually increasing doses of the allergens to which the patient is allergic. It has been demonstrated that this method of treatment induces an increased tolerance to the allergens responsible for the symptoms on subsequent exposure. The exact relationships between allergen, skin-sensitizing antibody (IgE) and the blocking antibody (IgG) have not been precisely established. Clinically confirmed immunological studies have adduced evidence of the efficacy of hyposensitization therapy.

Numerous controlled studies have demonstrated the clinical efficacy of immunotherapy with cat, dust mites and some pollen extracts. Nevertheless, responses are variable, and in a few studies patients reported no appreciable benefit.

Extracts containing Short Ragweed pollen bear a labeled potency declaration in terms of Antigen E content. Numerous studies have confirmed Antigen E (AgE) as the major antigen associated with Short Ragweed pollinosis.1 Therefore, it is essential that the physician be aware of AgE content of allergenic extract administered for hyposensitization therapy.

Some studies have indicated that for most patients a cumulative Antigen E dosage of less than 0.1 unit is not immunizing (sufficient to stimulate specific IgG antibodies).2 This, however, does not suggest that 0.1 unit is a maximum tolerated dose. Most moderately sensitive patients may tolerate a dosage of ten to fifty times greater. If results with this product are unsatisfactory with exquisitely sensitive patients who cannot tolerate an immunizing dose, the physician should consider alternative therapy.

One well-controlled study demonstrated that standard immunotherapy (gradually increasing doses of antigen given subcutaneously to a maximum tolerated peak dose) using crude ragweed extract of known Antigen E potency, was significantly superior to placebo and low dose immunotherapy (0.1 units AgE cumulative dose) in amelioration of symptoms associated with ragweed hay fever. These patients received a cumulative dose of 18-350 units Antigen E (median = 84.9 units). The maximum single dose ranged from 3.7 to 46.8 units (median = 11.1 units) prior to the ragweed hay fever season.10

Patients for this study were sensitive to Ragweed Antigen E, as determined by intradermal skin testing at a dose of 0.01 units AgE/mL. A series of 24 weekly injections were administered. Forty-seven percent of the patients experienced at least one systemic reaction with an average of 1.2 systemic reactions per patient. None of the patients were able to achieve the expected maximum dose (90 units of Antigen E) in the 24 weekly injection dosage schedule.

INDICATIONS AND USAGE

INDICATIONS & USAGE SECTION

Hyposensitization (injection) therapy is a treatment for patients exhibiting allergic reactions to seasonal pollens, dust, molds, animal danders, various other inhalants, and in situations where the offending allergen cannot be avoided.

Prior to initiation of therapy, the clinical sensitivity should be established by careful evaluation of the patient’s history confirmed by diagnostic skin testing. Hyposensitization should not be prescribed for sensitivities to allergens which can easily be avoided.

CONTRAINDICATIONS

CONTRAINDICATIONS SECTION

A patient should not be immunized with preparations of allergens to which the patient has not demonstrated symptoms, IgE antibodies, positive skin tests, or properly controlled challenge testing. In most cases, immunotherapy is not indicated for those allergens that can be eliminated or minimized by environmental control.

Patients on beta-blockers are not candidates for immunotherapy, as they can be non-responsive to beta-agonists that may be required to reverse a systemic reaction (also see WARNINGS AND ADVERSE REACTIONS).

In the presence of active symptoms such as rhinitis, wheezing, dyspnea, etc., the indication of immunotherapy must be weighed carefully against the risk of temporarily aggravating the symptoms by the injection itself.

Also, there is some evidence, although inconclusive, that routine immunizations may exacerbate autoimmune diseases.3,4,5 Hyposensitization should be given cautiously to patients with this predisposition. Patients with severe cardiorespiratory symptoms are at an additional risk during a systemic reaction. The physician must weigh risk to benefit in these cases.

WARNINGS

WARNINGS SECTION

Patients should always be observed for at least 20-30 minutes after any injection. In the event of a marked systemic reaction, application of a tourniquet above the injection site and administration of 0.2 mL to 1 mL (0.01 mg/kg) of Epinephrine Injection (1:1,000) is recommended. Maximal recommended dose for children between 2 and 12 years is 0.5 mL. The tourniquet is then gradually released at 15 minute intervals. Patients under treatment with beta-blockers may be refractory to the usual dose of epinephrine.

Volume expanders and vasopressor agents may be required to reverse hypotension. Inhalation bronchodilators and parenteral aminophylline may be required to reverse bronchospasm. In cases of respiratory obstruction, oxygen and intubation may be necessary. Life-threatening reaction unresponsive to the above may require cardiopulmonary resuscitation.

DO NOT GIVE INTRAVENOUSLY

After inserting the needle, but before injecting the dose, pull plunger of the syringe slightly. If blood returns in the syringe, discard the syringe and contents and repeat injection at another site.

Bulk concentrated extracts must be diluted for initial therapy.

Withhold allergenic extracts temporarily or reduce the dose in patients with any one of the following conditions:

- Severe rhinitis or asthma symptoms;

- Infection or flu accompanied by fever;

- Exposure to excessive amounts of clinically relevant allergen prior to therapy.

Patients with unstable asthma or steroid dependent asthmatics and patients with underlying cardiovascular disease are at greater risk. See PRECAUTIONS AND ADVERSE REACTIONS.

TRANSFER OF PATIENTS

From pyridine extracted alum complexed allergenic extracts to aqueous extracts and glycerinated: In order to avoid untoward reaction, it is recommended that therapy be initiated as though patients were previously untreated. The first dose should be related to the patient’s sensitivity, determined by history and confirmed by skin testing.

From unstandardized aqueous extracts to standardized aqueous extracts and glycerinated: The physician should establish the potency relationship, perhaps by comparative skin testing at equal concentration, prior to injecting the first standardized dose.

From aqueous alum precipitated or modified extracts to aqueous extracts and glycerinated: Since this subject has not been studied, it is recommended that therapy be initiated as if the patient were not previously treated.

PRECAUTIONS

PRECAUTIONS SECTION

INFORMATION TO PATIENTS:

Patients should be instructed to describe any active allergic symptoms such as rhinitis, wheezing, dyspnea, etc. prior to injection including any late reactions from previous administration. Patients should be instructed to remain in the office for 20 to 30 minutes after injection to monitor for adverse reactions. Also, see ADVERSE REACTIONS and WARNINGS Sections.

If the protective action of allergenic extract injections is considered essential for the patient’s welfare, appropriate symptomatic therapy with antihistaminic, adrenergic or other drugs might be needed either prior to or in conjunction with the allergenic extract injections.

GENERAL:

GENERAL PRECAUTIONS SECTION

  1. Objective assessment of pulmonary function such as Peak Expiratory Flow Rate (PEFR) before allergen administration may be useful in unstable asthmatic to reduce the chances of exacerbation of the patient’s asthma.
  2. Store allergenic extracts between 2° and 8°C at all times, even during use.
  3. Injections are to be given subcutaneously with the usual sterile precautions using a tuberculin syringe.
  4. Care must be taken to avoid injecting into a blood vessel. Pull gently on syringe plunger to determine if a blood vessel has been entered (See WARNINGS).
  5. Allergenic extracts slowly become less potent with age. During the course of treatment, it may be necessary to continue therapy with a vial of extract bearing a later expiration date. The initial dose of the extract bearing the later expiration date should be lowered to a safe, non-reaction eliciting level which can be confirmed by comparative skin testing using end-point titration.
  6. Use standard aseptic precautions when making dilutions. The first dose of the new extract should be reduced to at least 25% of the amount of the dosage from the previous extract.
  7. Extracts in 50% glycerin can cause discomfort at the site of the injection.

PREGNANCY - CATEGORY C:

PREGNANCY SECTION

Animal reproduction studies have not been conducted with allergenic extracts. It is also not known whether allergenic extracts can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity.

Controlled studies of hyposensitization with moderate to high doses of allergenic extracts during conception and all trimesters of pregnancy have failed to demonstrate any risk to the fetus or to the mother. However, on the basis of histamine’s known ability to contract uterine muscle, the release of significant amounts of histamine from allergen exposure or hyposensitization overdose should be avoided on theoretical grounds. Therefore, allergenic extracts should be used cautiously in a pregnant woman and only if clearly needed.

PEDIATRIC USE:

PEDIATRIC USE SECTION

Children can receive the same dose as adults, however, to minimize the discomfort associated with dose volume it may be advisable to reduce the volume of the dose by one-half and administer the injection at two different sites.

NURSING MOTHERS:

NURSING MOTHERS SECTION

It is not known if allergens administered subcutaneously appear in human milk. Because many drugs are excreted in human milk, caution should be exercised when allergenic extracts are administered to a nursing woman.

CARCINOGENESIS, MUTAGENESIS, IMPAIRMENT OF FERTILITY:

CARCINOGENESIS & MUTAGENESIS & IMPAIRMENT OF FERTILITY SECTION

Studies in animals have not been performed.

DRUG INTERACTIONS:

DRUG INTERACTIONS SECTION

Drugs can interfere with the performance of skin tests.6

Antihistamines: Response to mediator (histamine) released by allergens is suppressed by antihistamines. The length of suppression varies and is dependent on individual patient, type of antihistamine and length of time the patient has been on antihistamines. The duration of this suppression may be as little as 24 hours (chlorpheniramine), and can be as long as 40 days (astemizole).

Tricyclic Antidepressants: These exert a potent and sustained decrease of skin reactivity to histamine which may last for a few weeks.

Beta2 Agonists: Oral terbutaline and parenteral ephedrine, in general, have been shown to decrease allergen induced wheal.

Dopamine: Intravenous infusion of dopamine may inhibit skin test responses.

Beta Blocking Agents: Propranolol can significantly increase skin test reactivity (See WARNINGS).

Other Drugs: Short acting steroids, inhaled beta2 agonists, theophylline and cromolyn do not seem to affect skin test response.

ADVERSE REACTIONS

ADVERSE REACTIONS SECTION

Anaphylaxis and deaths following the injection of mite and other extracts have been reported by The British Committee on Safety in Medicine.7 Fatalities from immunotherapy in the United States since 1945 have been extensively reviewed by Lockey, R. F., et al8 and more recently by Reid, M. ⁠J. et al.9

With careful attention to dosage and administration, such reactions occur infrequently, but it must be remembered that allergenic extracts are highly potent to sensitive individuals and OVERDOSE could result in anaphylactic symptoms. Therefore, it is imperative that physicians administering allergenic extracts understand and be prepared for the treatment of severe reactions.

Local: Reactions at the site of injection may be immediate or delayed. Immediate wheal and erythema reactions are ordinarily of little consequence; but if very large, may be the first manifestation of a systemic reaction. If large local reactions occur, the patient should be observed for systemic symptoms for which treatment is outlined below.

Delayed reactions start several hours after injection with local edema, erythema, itching or pain. They are usually at their peak at 24 hours and usually require no treatment. Antihistamine drugs may be administered orally.

The next therapeutic dose should be reduced to the dose which did not elicit a reaction, and subsequent doses increased more slowly; i.e., use of intermediate dilutions.

Systemic: Systemic reactions are characterized by one or more of the following symptoms: Sneezing, mild to severe generalized urticaria, itching other than at the injection site, extensive or generalized edema, wheezing, asthma, dyspnea, cyanosis, tachycardia, lacrimation, marked perspiration, cough, hypotension, syncope and upper airway obstruction. Symptoms may progress to shock and death. Patients should always be observed for at least 20 to 30 minutes after any injection. Volume expanders and vasopressor agents may be required to reverse hypotension. Inhalational bronchodilators and parenteral aminophylline may be required to reverse bronchospasm. Severe airway obstruction, unresponsive to bronchodilator, may require tracheal intubation and use of oxygen. In the event of a marked systemic reaction, application of a tourniquet above the injection site and the administration of 0.2 mL to 1 mL of Epinephrine Injection (1:1,000) are recommended. Maximal recommended dose for children under 2 years of age is 0.3 mL. Maximal recommended dose for children between 2 and 12 years of age is 0.5 mL. The tourniquet should not be left in place without loosening for 90 seconds every 15 minutes.

The next therapeutic injection of extract should be reduced to the dose which did not elicit a reaction, and subsequent doses increased more slowly; i.e., use of intermediate dilutions.

OVERDOSAGE

OVERDOSAGE SECTION

Signs and symptoms of overdose are typically local and systemic reactions. For a description and management of overdose reactions, refer to “Adverse Reaction” section above.

DOSAGE AND ADMINISTRATION

DOSAGE & ADMINISTRATION SECTION

Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.

When diluting bulk extracts, use of Sterile Diluent for Allergenic Extracts or Sterile Diluent for Allergenic Extracts Normal Saline with HSA (albumin saline) is recommended. Dilutions should be made with sterile disposable syringes using aseptic technique. Commonly, 10 fold dilutions are used to achieve a desired concentration for initiation and continuation of immunotherapy. For example, transferring 0.5 mL of a 10,000 PNU/mL extract into 4.5 mL of diluent will yield 5 mL of extract at 1,000 PNU/mL. For weight volume products, a 1:100 w/v dilution may be prepared from a 1:10 w/v by transferring 0.5 mL of the 1:10 w/v to 4.5 mL of diluent. Prepare as many additional serial dilutions as necessary to reach the appropriate concentration.

Starting dose for immunotherapy is related directly to a patient’s sensitivity as determined by carefully executed skin testing. Degree of sensitivity can be established by determination of D50.11 A general rule is to begin at 1/10 of the dose that produces sum of erythema of 50 mm (approximately a 2+ positive skin test reaction).

For example, if a patient exhibits a 2+ intradermal reaction to 1 AU/mL, the first dose should be no higher than 0.05 mL of 0.1 AU/mL. Dosage may be increased by 0.05 mL each time until 0.5 mL is reached, at which time the next 10-fold more concentrated dilution can be used, beginning with 0.05 mL, if no untoward reaction is observed.

Interval between doses in the early stages of immunotherapy is no more than once to twice a week, and may gradually be increased to once every two weeks. Generally, maintenance injections may be given as infrequently as once every two weeks to once a month.

Injections are given subcutaneously, preferably in the arm. It is advantageous to give injections in alternate arms and routinely in the same area. In some patients, a local tolerance to the allergen may develop thus preventing a possible severe local reaction.

Formal stability studies for diluted and undiluted forms of unstandardized extracts have not been performed; therefore, it is recommended that minimal amounts of the concentrate be diluted so that the diluted product is used up within a relatively short period of time; i.e., preferably not more than four weeks.

PRE-SEASONAL METHOD OF TREATMENT

Treatment of hay fever by the pre-seasonal method should be started 6-10 weeks prior to the usual onset of symptoms. Therapy should be started early enough to permit a graduated series of doses at 2-7 day intervals. It is recommended that the larger doses be spaced 5-7 days apart.

Some physicians continue therapy into or through the season by repeating a reduced or MAINTENANCE dose at weekly or biweekly intervals. If during the season, hay fever symptoms develop, relief may be provided by giving supplemental treatment. If the last dose was well-tolerated and not more than 2 weeks has elapsed since it was given, this dose may be given again and repeated every 4 to 7 days.

PERENNIAL TREATMENT

The patient’s tolerance to the offending pollen or pollens is first established by the injection of a series of graduated doses as outlined in the PRE-SEASONAL METHOD, not necessarily given pre-seasonally, since perennial therapy may be begun at any time. After completion of the ascending series of injections, from 1/4 to 1/2 of the highest well-tolerated dose is continued at 2 to 3 week intervals throughout the year. Shortly before the usual onset of symptoms (4 to 5 weeks prior to the season) the interval between injections is shortened and the dosage is gradually increased, according to the Pre-Seasonal schedule, until maximum well-tolerated dose is again attained. This top dose should be reached just before the usual onset of symptoms at which time the treatment is discontinued. If patient’s symptoms persist, therapy may be continued at a reduced dosage level, usually 1/4 to 1/2 of the top dose.

DOSAGE ADJUSTMENTS

For Products Containing Short Ragweed.

In transferring patients from unstandardized to standardized product, the physician should establish the potency relationships, perhaps by comparative skin testing, prior to injecting the first standardized dose.

AgE is important in adjusting dosage of Short Ragweed extracts to accurately transfer a patient from older extracts to fresher material. In such cases, the dosage of AgE should be considered in addition to the W/V dilution or protein nitrogen units. Antigen E concentration continuously declines in Short Ragweed Pollen extracts at a rate that varies with the formulation of the product. Aqueous extracts retain Antigen E potency less effectively than glycerin 50% (v/v) extracts. These differences are reflected in the expiration date declared on the vial. The continuous decline should be considered. Also, where ragweed is a component of an allergen mixture, clinical response to the other components must be considered in adjustment of dosage based on AgE content alone. The usual course of immunotherapy is three to five years.

Caution: A small percent of individuals allergic to Short Ragweed are more sensitive to minor antigens such as Ra3 Ra5 than AgE. There is no correlation between the amount of these antigens and either AgE or PNU content.

NOTE: For extracts of Short Ragweed or equal part mixture of Short and Tall Ragweed refer to AgE dosage schedule. The AgE content for those products is indicated on the vial label. The physician may use the formula below to determine the AgE dosage for each injection.

AgE dosage can be monitored by using the following formula:

W/V compounded products:

Labeled AgE X Dose (mL) = dose in AgE

PNU compounded products:

Labeled AgE/mL X dose in PNU = dose in AgE

Labeled PNU/mL

HOW SUPPLIED

HOW SUPPLIED SECTION

  1. Concentrate in multiple dose vials:
  2. Sterile Diluent for Allergenic Extracts (Phenol Saline) is supplied in vials of 4.5 mL, 9.0 mL, 30 mL and 100 mL.

10 mL and 50 mL, single antigens or specified mixtures, potency expressed in PNU/mL (up to and including 100,000 PNU/mL) or W/V (up to and including 1:10 W/V), aqueous or in 50% glycerin, to be diluted prior to use. 1:10 w/v short ragweed extracts contain ≥ 300 units/mL of AgE.

STORAGE: To maintain stability of allergenic extracts, proper storage conditions are essential. Bulk concentrates and diluted extracts are to be stored at 2° to 8° C even during use. Bulk or diluted extracts are not to be frozen. Do not use after the expiration date shown on the vial label.

REFERENCES

REFERENCES SECTION

  1. Norman, P.S. et al: Immunotherapy of hayfever with ragweed antigen E. Comparisons with whole pollen extract and placebo. J. Allergy 42:93, 1968.
  2. Van Metre, T.E. et al: A controlled study of the effectiveness of the Rinkel method of immunotherapy for ragweed pollen hayfever. J. Allergy Clin. Immunol. 65:288, 1980.
  3. Umetsu, D.T. et al: Serum sickness triggered by anaphylaxis: a complication of immunotherapy. J. Allergy Clin. Immunol. 76:713, 1985.
  4. Phannphak, P. and Kohler, P.F.: Onset of polyarteritis nodosa during allergic hyposenitization treatment. Am. J. Med. 68:479, 1980.
  5. Kohler, P.F.: Immune complexes and allergic disease. In: Middleton et al: Allergy Principles and Practice 3rd Ed. St. Louis: CV Mosby, 1988:167.
  6. Bousquet, J.: In vivo methods for the study of allergy: skin test, techniques, and interpretation. In: Middleton et al: Allergy Principles and Practice 3rd Ed. St. Louis: CV Mosby, 1988:167.
  7. Committee on the Safety of Medicines. CSM update: desensitising vaccines. Brit Med. J. 293:948,1986.
  8. Lockey, R.F. et al: Fatalities from immunotherapy (IT) and skin testing (ST). J. Allergy Clin. Immunol. 79:660, 1987.
  9. Reid, M.J. et al: Survey of fatalities from skin testing and immunotherapy. 1985-1989. J. Allergy Clin. Immunol.;92:6, 1993.
  10. Van Metre, T.E. et al: A controlled study of the effectiveness of the Rinkel method and the current standard method of immunotherapy for ragweed pollen hayfever. J. Allergy Clin. Immunol. 66:500, 1980.
  11. Turkeltaub, P.C., Rastogi, S.C., Baer, H., et al: A standardized quantitative skin-test assay of allergen potency and stability: studies on the allergen dose-response curve and effect of wheal, erythema, and patient selection on assay results, J. Allergy Clin. Immunol. 70:343, 1982.

Revised April 2017                                                       158M      

© ALK-Abelló, Inc. 

Distributed in Canada by:

ALK-Abelló Pharmaceuticals, Inc.

#35-151 Brunel Road

Mississauga, Ontario

Canada L4Z 2H6

PRINCIPAL DISPLAY PANEL

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

ALLERGENIC EXTRACT
mL sterile multiple dose vial

PRINCIPAL DISPLAY PANEL ALLERGENIC EXTRACT mL sterile multiple dose vialPRINCIPAL DISPLAY PANEL ALLERGENIC EXTRACT mL sterile multiple dose vial

Product Linked Resources#

Resource, Code type, Value table
ResourceCode typeValueEquivalent identifiersSource image
BarcodeData Matrix(01)00842741106845(17)220710(21)E90CZ8XKRM(10)0003504447GTIN-14: 00842741106845
GTIN-12: 842741106845
UPC-A: 842741106845
EAN-13: 0842741106845
GTIN storage (14 digits): 00842741106845
nonstandardized-allergenic-products-02.jpg

DailyMed Product Concepts#

Product concept, Relation, Version table
Product conceptRelationVersionEffective
fb7ab793-2c12-4079-b100-a64f73bef25aProduct name420240712
362d7abb-94e6-4c60-9a58-266894157713Product name120231023
b0cbf770-6cc3-4aa4-9158-755110c2b9f7Product name220230717
dc7c5daa-021f-40dd-b00d-63982cb2067aProduct name120230426
6bd95106-a412-1dad-b9cc-4cb74bfb27ceProduct name220230315
f1e0dc7e-7d61-4625-b6d9-4894927679d7Product name220211025
08ffbcbf-26df-b99c-1dab-64fc4cfae89fProduct name520200925
e4870509-7e28-6f92-f0be-dd3dd889a9cfProduct name520200810
6e9d4a47-c464-b93e-aebc-ad7bffc9c4cdProduct name220190619
444b3e50-f226-46ef-bfca-2e7035d140cdProduct name120190611
816b97af-edc5-4060-aff1-b814bdbcad50Product name120190415
7cda52fc-125f-421c-8fea-bc1974370c49Product name220180703
419aab54-5d5a-4146-9453-026d4a9991beProduct name220170525
08ffbcbf-26df-b99c-1dab-64fc4cfae89fProduct name220160823
d5e51f11-ad28-caa4-4b49-4143974782adProduct name120150831
290f523a-f9db-9774-b5a9-e1f908ac1782Product name120150828
89dac932-b90a-4410-9ab1-84c53e57de25Product name120150316
5668b646-cd56-c3c7-bdea-3f6b1a8840dbProduct name120140508
684ea482-2e8b-14af-5664-b98f1e402036Product name120140508
810ab97e-f109-f41c-7c83-6a652a9cbf43Product name120140508
87711080-88eb-65c5-b2dd-bf99e700a372Product name120140508
8dbefedf-0a0d-a224-5a3c-66dc9e11c2ddProduct name120140508
b060cc1a-fe47-856b-0b77-4448b5963de8Product name120140508
c6b65c52-69c7-df49-550a-a50c137f6218Product name120140508
ec2149b3-5c6d-5344-f757-c86411073075Product name120140508
ed912195-5da0-0f2f-6f4b-3ef17710cbe3Product name120140508

DailyMed Billing Units#

Package NDC, Billing unit, Product NDC table
Package NDCBilling unitProduct NDCDailyMed indexing SPLSPL versionEffective
0268-1280-10ML - Milliliter0268-12805dd18780-8a4b-43a1-8346-64a4ab31d3c912015-11-12
0268-1121-10ML - Milliliter0268-11212f300cff-0644-43cc-ade6-1d56798b3e3d12016-09-02
0268-0626-10ML - Milliliter0268-06269e530c1b-89c2-4a7f-ad79-1111762ca8c612015-09-10
0268-0626-50ML - Milliliter0268-0626a9bdbe16-824f-453c-a3cd-17462ba35bcf12016-03-04
0268-0653-10ML - Milliliter0268-0653e0828d0b-871a-4832-981a-1e9a2267d5db12025-08-11
0268-0628-10ML - Milliliter0268-0628931dd802-4c82-45a8-aa72-73e8223e5dcd12015-11-12
0268-1001-10ML - Milliliter0268-10018414a173-43c5-4efc-80d7-f0e395c6fccb12016-01-13
0268-1008-10ML - Milliliter0268-100855eff769-390c-443d-aff6-62e29f1e81a112016-02-04
0268-1023-10ML - Milliliter0268-10238e990daa-11e9-438e-8c71-b668d139b86e12015-11-12

DailyMed Socrata Ingredients#

Ingredient, Type, UNII table
IngredientTypeUNIISPL versionUploaded
ACACIAACTIVE INGREDIENT5C5403N26O3
ACER NEGUNDO POLLENACTIVE INGREDIENTP6K070AR8V3
ACER RUBRUM POLLENACTIVE INGREDIENT700NK45C763
ACER SACCHARUM POLLENACTIVE INGREDIENTV38QUQ78613
ACREMONIUM STRICTUMACTIVE INGREDIENT3F36V0451W3
AILANTHUS ALTISSIMA POLLENACTIVE INGREDIENT2A64U81OQ33
ALNUS INCANA SUBSP. RUGOSA POLLENACTIVE INGREDIENT605T96G8Y53
ALTERNARIA ALTERNATAACTIVE INGREDIENT52B29REC7H3
AMARANTHUS PALMERI POLLENACTIVE INGREDIENT1GH3WV23KH3
AMARANTHUS RETROFLEXUS POLLENACTIVE INGREDIENT73B14PX5FW3
AMARANTHUS SPINOSUS POLLENACTIVE INGREDIENT380W4HYR6N3
AMARANTHUS TUBERCULATUS POLLENACTIVE INGREDIENT92N6W6KO2G3
AMBROSIA ACANTHICARPA POLLENACTIVE INGREDIENTU2AI3H2J5Y3
AMBROSIA ARTEMISIIFOLIA POLLENACTIVE INGREDIENTK20Y81ACO33
AMBROSIA BIDENTATA POLLENACTIVE INGREDIENTM3S672G75O3
AMBROSIA PSILOSTACHYA POLLENACTIVE INGREDIENTRX18M46K8L3
AMBROSIA TENUIFOLIA POLLENACTIVE INGREDIENT57W5SO585B3
AMBROSIA TRIFIDA POLLENACTIVE INGREDIENTKU1V1898XX3
ARTEMISIA FRIGIDA POLLENACTIVE INGREDIENT5AN5LR8L3F3
ARTEMISIA TRIDENTATA POLLENACTIVE INGREDIENTYI19RB8YFD3
ARTEMISIA VULGARIS POLLENACTIVE INGREDIENTANT994T71D3
ASPERGILLUS FUMIGATUSACTIVE INGREDIENTX88DF51T483
ASPERGILLUS NIGER VAR. NIGERACTIVE INGREDIENT9IOA40ANG63
ATRIPLEX WRIGHTII POLLENACTIVE INGREDIENTYB1308W43O3
AUREOBASIDIUM PULLULANS VAR. PULLUTANSACTIVE INGREDIENTD1A2NG69CK3
BETULA LENTA POLLENACTIVE INGREDIENTJQ5HI5004M3
BETULA NIGRA POLLENACTIVE INGREDIENT93963RFO1P3
BLATELLA GERMANICAACTIVE INGREDIENTG9O67I0A8Q3
BOS TAURUS SKINACTIVE INGREDIENT7J12CD6O9L3
BOTRYTIS CINEREAACTIVE INGREDIENTTBW53313S73
BROMUS INERMIS POLLENACTIVE INGREDIENT766QT72BK63
CANDIDA ALBICANSACTIVE INGREDIENT4D7G21HDBC3
CANIS LUPUS FAMILIARIS SKINACTIVE INGREDIENTX2W7CLE97T3
CARYA ILLINOINENSIS POLLENACTIVE INGREDIENTPYO4JR720Y3
CASUARINA EQUISETIFOLIA POLLENACTIVE INGREDIENTOZJ4OE173N3
CAVIA PORCELLUS SKINACTIVE INGREDIENTGM3H4U6QS83
CEIBA PENTANDRA FIBERACTIVE INGREDIENT758Z9H9WV93
CELTIS OCCIDENTALIS POLLENACTIVE INGREDIENT68R9X9Y96X3
CHAETOMIUM GLOBOSUMACTIVE INGREDIENT5016WB8B8A3
CHENOPODIUM ALBUM POLLENACTIVE INGREDIENT098LKX5NCN3
CHENOPODIUM AMBROSIOIDES POLLENACTIVE INGREDIENTWIB701MW2H3
CLADOSPORIUM CLADOSPORIOIDESACTIVE INGREDIENT4ZWY20GTGO3
CLADOSPORIUM SPHAEROSPERMUMACTIVE INGREDIENTP87YCA1U8R3
COCHLIOBOLUS SATIVUSACTIVE INGREDIENT3LN5B70U4W3
CORYLUS AMERICANA POLLENACTIVE INGREDIENTZGS382Y3AV3
COTTON FIBERACTIVE INGREDIENT70LDW53ROO3
COTTON SEEDACTIVE INGREDIENTDI0ZRJ0MXN3
CUPRESSUS ARIZONICA POLLENACTIVE INGREDIENT232DMH0XVF3
DISTICHLIS SPICATA POLLENACTIVE INGREDIENTGOA51670YV3
ELYMUS REPENS POLLENACTIVE INGREDIENTON2T85TA2O3
EPICOCCUM NIGRUMACTIVE INGREDIENT87U156LEN73
EQUUS CABALLUS SKINACTIVE INGREDIENT88VZV9HGT43
EUCALYPTUS GLOBULUS POLLENACTIVE INGREDIENT7XW7TB10X93
EUPATORIUM CAPILLIFOLIUM POLLENACTIVE INGREDIENTB67NF86HF03
FAGUS GRANDIFOLIA POLLENACTIVE INGREDIENT34X886W1H43
FRAXINUS AMERICANA POLLENACTIVE INGREDIENTG684LX721Q3
FRAXINUS VELUTINA POLLENACTIVE INGREDIENTLJT6I6Z8FD3
FUSARIUM OXYSPORUM VASINFECTUMACTIVE INGREDIENT6M98DC08TZ3
HELMINTHOSPORIUM SOLANIACTIVE INGREDIENTU6Z259H8153
HOLCUS LANATUS POLLENACTIVE INGREDIENT70O1TP6H013
HOUSE DUSTACTIVE INGREDIENTEYO007VX983
IVA ANNUA VAR. ANNUA POLLENACTIVE INGREDIENTY2U5S5PF223
IVA XANTHIFOLIA POLLENACTIVE INGREDIENTV80TPZ0T6J3
JUGLANS NIGRA POLLENACTIVE INGREDIENT1BV28146ZR3
JUGLANS REGIA POLLENACTIVE INGREDIENTARW43087I13
JUNIPERUS ASHEI POLLENACTIVE INGREDIENT544F8MEY0Y3
JUNIPERUS CALIFORNICA POLLENACTIVE INGREDIENT0H1V4V5V9L3
JUNIPERUS VIRGINIANA POLLENACTIVE INGREDIENTPY0JA16R2G3
KOCHIA SCOPARIA POLLENACTIVE INGREDIENT07A108ZKW53
LIGUSTRUM VULGARE POLLENACTIVE INGREDIENTY3FRX92Z0E3
LIQUIDAMBAR STYRACIFLUA POLLENACTIVE INGREDIENT5Q246DS5BS3
LOLIUM PERENNE SSP. MULTIFLORUM POLLENACTIVE INGREDIENTVJI0WKK7363
MEDICAGO SATIVA POLLENACTIVE INGREDIENTG515RAI9FY3
MELALEUCA QUINQUENERVIA POLLENACTIVE INGREDIENTNX974IRT8E3
MORELLA CERIFERA POLLENACTIVE INGREDIENTLC8MEV9S893
MORUS ALBA POLLENACTIVE INGREDIENT3I9T68187H3
MORUS RUBRA POLLENACTIVE INGREDIENT9LYI4RTZ523
MUCOR PLUMBEUSACTIVE INGREDIENTD7401PWY6E3
MUS MUSCULUS SKINACTIVE INGREDIENT390AN9GB093
NEUROSPORA INTERMEDIAACTIVE INGREDIENT2072U60DUI3
OLEA EUROPAEA POLLENACTIVE INGREDIENT43R41XZ6273
ORRISACTIVE INGREDIENT8N6VTJ9IWV3
PASPALUM NOTATUM POLLENACTIVE INGREDIENTV003SHB7VK3
PENICILLIUM CHRYSOGENUM VAR. CHRYSOGENUMACTIVE INGREDIENT3Y1PE1GCIG3
PERIPLANETA AMERICANAACTIVE INGREDIENT2RQ1L9N0893
PHOMA EXIGUA VAR. EXIGUAACTIVE INGREDIENT8JAG41IE4M3
PINUS ECHINATA POLLENACTIVE INGREDIENT96LRW147653
PINUS STROBUS POLLENACTIVE INGREDIENTTX1ER5UV3T3
PLANTAGO LANCEOLATA POLLENACTIVE INGREDIENTDO87T1U2CI3
PLATANUS OCCIDENTALIS POLLENACTIVE INGREDIENTE03U1K03LK3
POA ANNUA POLLENACTIVE INGREDIENT7U437HHU5C3
POPULUS ALBA POLLENACTIVE INGREDIENTVU8C8SB23P3
POPULUS DELTOIDES POLLENACTIVE INGREDIENT476DVV63WP3
POPULUS DELTOIDES SUBSP. MONILIFERA POLLENACTIVE INGREDIENT5928LJ14413
POPULUS FREMONTII POLLENACTIVE INGREDIENT426RHB43023
POPULUS TREMULOIDES POLLENACTIVE INGREDIENT928OC2TJDA3
PROSOPIS JULIFLORA POLLENACTIVE INGREDIENT6EIJ3D04MR3
PYRETHRUM CINERARIIFOLIUMACTIVE INGREDIENTCGF76TP7X63
QUERCUS AGRIFOLIA POLLENACTIVE INGREDIENTVOT5MA71M73
QUERCUS ALBA POLLENACTIVE INGREDIENTZ4Y9ZSV4KK3
QUERCUS RUBRA POLLENACTIVE INGREDIENTSVW19ET93C3
QUERCUS VIRGINIANA POLLENACTIVE INGREDIENT8KDG09A4GO3
RABBITACTIVE INGREDIENTO5V0F26RUW3
RHIZOPUS ARRHIZUS VAR. ARRHIZUSACTIVE INGREDIENT8476849N1Y3
RHODOTORULA RUBRAACTIVE INGREDIENT15W81V867R3
ROBINIA PSEUDOACACIA POLLENACTIVE INGREDIENT8003NOJ82F3
RUMEX ACETOSELLA POLLENACTIVE INGREDIENTN52MIQ81ZW3
RUMEX CRISPUS POLLENACTIVE INGREDIENTV825XJG64G3
SACCHAROMYCES CEREVISIAEACTIVE INGREDIENT978D8U419H3
SALIX NIGRA POLLENACTIVE INGREDIENT6M2JIH93ZN3
SALSOLA KALI POLLENACTIVE INGREDIENT2MH135KC6G3
SCHINUS MOLLE POLLENACTIVE INGREDIENTM0G28FH9K13
SOLIDAGO CANADENSIS POLLENACTIVE INGREDIENT644CZ16IR53
SORGHUM HALEPENSE POLLENACTIVE INGREDIENT577VA5B4HP3
STEMPHYLIUM SOLANIACTIVE INGREDIENT1IEK4UDP5M3
SYAGRUS ROMANZOFFIANA POLLENACTIVE INGREDIENT84ZOM591BB3
TAXODIUM DISTICHUM POLLENACTIVE INGREDIENTO12H03B41R3
TRICHOPHYTON MENTAGROPHYTESACTIVE INGREDIENT199I7J3JIV3
TRITICUM AESTIVUM POLLENACTIVE INGREDIENTF1KAH8374D3
ULMUS AMERICANA POLLENACTIVE INGREDIENT89BAT511BD3
ULMUS CRASSIFOLIA POLLENACTIVE INGREDIENTG82398SD3I3
ULMUS PUMILA POLLENACTIVE INGREDIENT030R993R8E3
USTILAGO MAYDISACTIVE INGREDIENT4K7Z7K7SWG3
USTILAGO TRITICIACTIVE INGREDIENTBV82OL2IZ83
XANTHIUM STRUMARIUM VAR. CANADENSE POLLENACTIVE INGREDIENT0ZK6G3W3BI3
ZEA MAYS POLLENACTIVE INGREDIENT74PD8J616H3
ACACIAACTIVE MOIETY5C5403N26O3
ACER NEGUNDO POLLENACTIVE MOIETYP6K070AR8V3
ACER RUBRUM POLLENACTIVE MOIETY700NK45C763
ACER SACCHARUM POLLENACTIVE MOIETYV38QUQ78613
ACREMONIUM STRICTUMACTIVE MOIETY3F36V0451W3
AILANTHUS ALTISSIMA POLLENACTIVE MOIETY2A64U81OQ33
ALNUS INCANA SUBSP. RUGOSA POLLENACTIVE MOIETY605T96G8Y53
ALTERNARIA ALTERNATAACTIVE MOIETY52B29REC7H3
AMARANTHUS PALMERI POLLENACTIVE MOIETY1GH3WV23KH3
AMARANTHUS RETROFLEXUS POLLENACTIVE MOIETY73B14PX5FW3
AMARANTHUS SPINOSUS POLLENACTIVE MOIETY380W4HYR6N3
AMARANTHUS TUBERCULATUS POLLENACTIVE MOIETY92N6W6KO2G3
AMBROSIA ACANTHICARPA POLLENACTIVE MOIETYU2AI3H2J5Y3
AMBROSIA ARTEMISIIFOLIA POLLENACTIVE MOIETYK20Y81ACO33
AMBROSIA BIDENTATA POLLENACTIVE MOIETYM3S672G75O3
AMBROSIA PSILOSTACHYA POLLENACTIVE MOIETYRX18M46K8L3
AMBROSIA TENUIFOLIA POLLENACTIVE MOIETY57W5SO585B3
AMBROSIA TRIFIDA POLLENACTIVE MOIETYKU1V1898XX3
ARTEMISIA FRIGIDA POLLENACTIVE MOIETY5AN5LR8L3F3
ARTEMISIA TRIDENTATA POLLENACTIVE MOIETYYI19RB8YFD3
ARTEMISIA VULGARIS POLLENACTIVE MOIETYANT994T71D3
ASPERGILLUS FUMIGATUSACTIVE MOIETYX88DF51T483
ASPERGILLUS NIGER VAR. NIGERACTIVE MOIETY9IOA40ANG63
ATRIPLEX WRIGHTII POLLENACTIVE MOIETYYB1308W43O3
AUREOBASIDIUM PULLULANS VAR. PULLUTANSACTIVE MOIETYD1A2NG69CK3
BETULA LENTA POLLENACTIVE MOIETYJQ5HI5004M3
BETULA NIGRA POLLENACTIVE MOIETY93963RFO1P3
BLATELLA GERMANICAACTIVE MOIETYG9O67I0A8Q3
BOS TAURUS SKINACTIVE MOIETY7J12CD6O9L3
BOTRYTIS CINEREAACTIVE MOIETYTBW53313S73
BROMUS INERMIS POLLENACTIVE MOIETY766QT72BK63
CANDIDA ALBICANSACTIVE MOIETY4D7G21HDBC3
CANIS LUPUS FAMILIARIS SKINACTIVE MOIETYX2W7CLE97T3
CARYA ILLINOINENSIS POLLENACTIVE MOIETYPYO4JR720Y3

Products#

Every source-derived product name is available through these pages.

DailyMed product names page 1 of 5 · 168 matching rows.

NDC Codes#

Product NDC, Package NDC table
Product NDCPackage NDC
0268-12790268-1279-50
0268-12800268-1280-10, 0268-1280-50
0268-11210268-1121-50, 0268-1121-10
0268-06260268-0626-10, 0268-0626-50
0268-06530268-0653-10
0268-06280268-0628-10, 0268-0628-50
0268-10010268-1001-10, 0268-1001-50
0268-10070268-1007-50
0268-10080268-1008-10, 0268-1008-50
0268-10120268-1012-10, 0268-1012-50
0268-10160268-1016-50
0268-10220268-1022-10, 0268-1022-50
0268-10230268-1023-10, 0268-1023-50
0268-10240268-1024-50
0268-10340268-1034-10, 0268-1034-50
0268-10350268-1035-10, 0268-1035-50
0268-10410268-1041-50
0268-10420268-1042-10, 0268-1042-50
0268-10460268-1046-50
0268-10470268-1047-10, 0268-1047-50
0268-10560268-1056-50
0268-10620268-1062-50
0268-10630268-1063-50, 0268-1063-10
0268-10690268-1069-10, 0268-1069-50
0268-09450268-0945-50, 0268-0945-10
0268-06030268-0603-50, 0268-0603-10
0268-06150268-0615-10, 0268-0615-50
0268-06190268-0619-50, 0268-0619-10
0268-06200268-0620-10, 0268-0620-50
0268-06210268-0621-50, 0268-0621-10
0268-06310268-0631-50, 0268-0631-10
0268-06380268-0638-10, 0268-0638-50
0268-06500268-0650-10
0268-06510268-0651-10
0268-07070268-0707-10, 0268-0707-50
0268-07140268-0714-10, 0268-0714-50
0268-10700268-1070-10, 0268-1070-50
0268-10800268-1080-50, 0268-1080-10
0268-10810268-1081-50, 0268-1081-10
0268-10870268-1087-10, 0268-1087-50
0268-10920268-1092-50
0268-10930268-1093-50, 0268-1093-10
0268-10970268-1097-50, 0268-1097-10
0268-10980268-1098-50, 0268-1098-10
0268-11020268-1102-50, 0268-1102-10
0268-11100268-1110-10, 0268-1110-50
0268-11110268-1111-10, 0268-1111-50
0268-11120268-1112-10, 0268-1112-50
0268-11470268-1147-50, 0268-1147-10
0268-11510268-1151-50, 0268-1151-10
0268-11520268-1152-50, 0268-1152-10
0268-11590268-1159-50, 0268-1159-10
0268-11600268-1160-50, 0268-1160-10
0268-11650268-1165-50, 0268-1165-10
0268-11680268-1168-50, 0268-1168-10
0268-11690268-1169-50, 0268-1169-10
0268-11700268-1170-50
0268-11770268-1177-50
0268-11780268-1178-50
0268-11820268-1182-50, 0268-1182-10
0268-11850268-1185-50
0268-11860268-1186-50, 0268-1186-10
0268-11920268-1192-50, 0268-1192-10
0268-11260268-1126-10, 0268-1126-50
0268-11270268-1127-10, 0268-1127-50
0268-11380268-1138-50
0268-11390268-1139-50
0268-11430268-1143-50, 0268-1143-10
0268-11980268-1198-50
0268-11990268-1199-50, 0268-1199-10
0268-12140268-1214-10, 0268-1214-50
0268-12150268-1215-10, 0268-1215-50
0268-12160268-1216-50
0268-12230268-1223-50
0268-12240268-1224-50, 0268-1224-10
0268-12320268-1232-50, 0268-1232-10
0268-12330268-1233-50, 0268-1233-10
0268-12340268-1234-50
0268-12380268-1238-10, 0268-1238-50
0268-12390268-1239-10, 0268-1239-50
0268-12400268-1240-10, 0268-1240-50
0268-12490268-1249-10, 0268-1249-50
0268-12520268-1252-10, 0268-1252-50
0268-12530268-1253-10, 0268-1253-50
0268-12540268-1254-50
0268-12580268-1258-50
0268-12590268-1259-10, 0268-1259-50
0268-12630268-1263-10, 0268-1263-50
0268-12640268-1264-10, 0268-1264-50
0268-12650268-1265-50
0268-12970268-1297-10, 0268-1297-50
0268-12980268-1298-10, 0268-1298-50
0268-13040268-1304-10, 0268-1304-50
0268-13050268-1305-10, 0268-1305-50
0268-13100268-1310-50
0268-13110268-1311-10, 0268-1311-50
0268-13190268-1319-10, 0268-1319-50
0268-13220268-1322-50
0268-13230268-1323-10, 0268-1323-50
0268-13270268-1327-10, 0268-1327-50
0268-13280268-1328-10, 0268-1328-50
0268-13290268-1329-50
0268-13400268-1340-10, 0268-1340-50
0268-13470268-1347-50
0268-13480268-1348-10, 0268-1348-50
0268-13540268-1354-10, 0268-1354-50
0268-13550268-1355-10, 0268-1355-50
0268-13610268-1361-10
0268-13640268-1364-50, 0268-1364-10
0268-13650268-1365-50, 0268-1365-10
0268-13710268-1371-50
0268-13720268-1372-10
0268-13760268-1376-50
0268-13820268-1382-50
0268-13830268-1383-10, 0268-1383-50
0268-13900268-1390-50
0268-13940268-1394-10, 0268-1394-50
0268-13950268-1395-10, 0268-1395-50
0268-14000268-1400-10, 0268-1400-50
0268-14050268-1405-50
0268-14060268-1406-50, 0268-1406-10
0268-14120268-1412-50
0268-14130268-1413-50, 0268-1413-10
0268-14180268-1418-50
0268-14240268-1424-50, 0268-1424-10
0268-15310268-1531-10, 0268-1531-50
0268-15320268-1532-10, 0268-1532-50
0268-14390268-1439-50
0268-14400268-1440-50, 0268-1440-10
0268-14450268-1445-50
0268-14460268-1446-10, 0268-1446-50
0268-14530268-1453-10, 0268-1453-50
0268-14540268-1454-10, 0268-1454-50
0268-14710268-1471-50, 0268-1471-10
0268-14720268-1472-50, 0268-1472-10
0268-14930268-1493-50
0268-14940268-1494-50, 0268-1494-10
0268-15010268-1501-50, 0268-1501-10
0268-15020268-1502-50, 0268-1502-10
0268-15120268-1512-10, 0268-1512-50
0268-15130268-1513-10, 0268-1513-50
0268-15190268-1519-50, 0268-1519-10
0268-15240268-1524-50, 0268-1524-10
0268-15250268-1525-50, 0268-1525-10
0268-16030268-1603-10, 0268-1603-50

Ingredients#

Every source-derived ingredient row is available through these pages.

DailyMed ingredient rows page 1 of 24 · 946 matching rows.

Source Document#

Source XML

Older Hydrated Versions#

Version, Effective date, Source table
VersionEffective dateSourceHydrated
132023-05-17full-release2026-06-01 02:50:49

Inactive ingredient matches#

Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.

Inactive ingredient links page 1 of 45 · 2,677 matching rows.

DailyMed ingredient, IID ingredient, UNII table
DailyMed ingredientIID ingredientUNIIDosage form / routePotencyMaximum daily exposureMatch
SODIUM BICARBONATESODIUM BICARBONATE8MDF5V39QOINJECTION, SOLUTION / INTRAVENOUS52 mgExact identifier — unii+dosage form
767 equally ranked IID candidates
HYDROCHLORIC ACIDHYDROCHLORIC ACIDQTT17582CBINJECTION, SOLUTION / SUBCUTANEOUS1037 mgExact identifier — unii+route+dosage form
382 equally ranked IID candidates
GLYCERINGLYCERINPDC6A3C0OXINJECTION, SOLUTION / SUBCUTANEOUS15 %w/vExact identifier — unii+route+dosage form
382 equally ranked IID candidates
HYDROCHLORIC ACIDHYDROCHLORIC ACIDQTT17582CBINJECTION, SOLUTION / SUBCUTANEOUS1037 mgExact identifier — unii+route+dosage form
382 equally ranked IID candidates
SODIUM BICARBONATESODIUM BICARBONATE8MDF5V39QOINJECTION / SUBCUTANEOUSADJ PHExact identifier — unii+route
767 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IINJECTION, SOLUTION / SUBCUTANEOUS1 %w/vExact identifier — unii+route+dosage form
382 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IINJECTION, SOLUTION / SUBCUTANEOUS1 %w/vExact identifier — unii+route+dosage form
382 equally ranked IID candidates
SODIUM CHLORIDESODIUM CHLORIDE451W47IQ8XINJECTION, SOLUTION / SUBCUTANEOUS1486 mgExact identifier — unii+route+dosage form
382 equally ranked IID candidates
SODIUM CHLORIDESODIUM CHLORIDE451W47IQ8XINJECTION, SOLUTION / SUBCUTANEOUS1486 mgExact identifier — unii+route+dosage form
382 equally ranked IID candidates
GLYCERINGLYCERINPDC6A3C0OXINJECTION, SOLUTION / SUBCUTANEOUS15 %w/vExact identifier — unii+route+dosage form
382 equally ranked IID candidates
SODIUM CHLORIDESODIUM CHLORIDE451W47IQ8XINJECTION, SOLUTION / SUBCUTANEOUS1486 mgExact identifier — unii+route+dosage form
382 equally ranked IID candidates
GLYCERINGLYCERINPDC6A3C0OXINJECTION, SOLUTION / SUBCUTANEOUS15 %w/vExact identifier — unii+route+dosage form
382 equally ranked IID candidates
SODIUM BICARBONATESODIUM BICARBONATE8MDF5V39QOINJECTION, SOLUTION / INTRAVENOUS52 mgExact identifier — unii+dosage form
767 equally ranked IID candidates
SODIUM BICARBONATESODIUM BICARBONATE8MDF5V39QOINJECTION / SUBCUTANEOUSADJ PHExact identifier — unii+route
767 equally ranked IID candidates
HYDROCHLORIC ACIDHYDROCHLORIC ACIDQTT17582CBINJECTION, SOLUTION / SUBCUTANEOUS1037 mgExact identifier — unii+route+dosage form
382 equally ranked IID candidates
SODIUM BICARBONATESODIUM BICARBONATE8MDF5V39QOINJECTION / SUBCUTANEOUSADJ PHExact identifier — unii+route
767 equally ranked IID candidates
PHENOLPHENOL339NCG44TVINJECTION, SOLUTION / SUBCUTANEOUS0.55 %w/vExact identifier — unii+route+dosage form
382 equally ranked IID candidates
GLYCERINGLYCERINPDC6A3C0OXINJECTION, SOLUTION / SUBCUTANEOUS15 %w/vExact identifier — unii+route+dosage form
382 equally ranked IID candidates
HYDROCHLORIC ACIDHYDROCHLORIC ACIDQTT17582CBINJECTION, SOLUTION / SUBCUTANEOUS1037 mgExact identifier — unii+route+dosage form
382 equally ranked IID candidates
SODIUM BICARBONATESODIUM BICARBONATE8MDF5V39QOINJECTION / SUBCUTANEOUSADJ PHExact identifier — unii+route
767 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IINJECTION, SOLUTION / SUBCUTANEOUS1 %w/vExact identifier — unii+route+dosage form
382 equally ranked IID candidates
PHENOLPHENOL339NCG44TVINJECTION, SOLUTION / SUBCUTANEOUS0.55 %w/vExact identifier — unii+route+dosage form
382 equally ranked IID candidates
SODIUM BICARBONATESODIUM BICARBONATE8MDF5V39QOINJECTION, SOLUTION / INTRAVENOUS52 mgExact identifier — unii+dosage form
767 equally ranked IID candidates
SODIUM CHLORIDESODIUM CHLORIDE451W47IQ8XINJECTION, SOLUTION / SUBCUTANEOUS1486 mgExact identifier — unii+route+dosage form
382 equally ranked IID candidates
SODIUM BICARBONATESODIUM BICARBONATE8MDF5V39QOINJECTION / SUBCUTANEOUSADJ PHExact identifier — unii+route
767 equally ranked IID candidates
SODIUM BICARBONATESODIUM BICARBONATE8MDF5V39QOINJECTION / SUBCUTANEOUSADJ PHExact identifier — unii+route
767 equally ranked IID candidates
SODIUM BICARBONATESODIUM BICARBONATE8MDF5V39QOINJECTION / SUBCUTANEOUSADJ PHExact identifier — unii+route
767 equally ranked IID candidates
HYDROCHLORIC ACIDHYDROCHLORIC ACIDQTT17582CBINJECTION, SOLUTION / SUBCUTANEOUS1037 mgExact identifier — unii+route+dosage form
382 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IINJECTION, SOLUTION / SUBCUTANEOUS1 %w/vExact identifier — unii+route+dosage form
382 equally ranked IID candidates
HYDROCHLORIC ACIDHYDROCHLORIC ACIDQTT17582CBINJECTION, SOLUTION / SUBCUTANEOUS1037 mgExact identifier — unii+route+dosage form
382 equally ranked IID candidates
SODIUM BICARBONATESODIUM BICARBONATE8MDF5V39QOINJECTION / SUBCUTANEOUSADJ PHExact identifier — unii+route
767 equally ranked IID candidates
SODIUM BICARBONATESODIUM BICARBONATE8MDF5V39QOINJECTION, SOLUTION / INTRAVENOUS52 mgExact identifier — unii+dosage form
767 equally ranked IID candidates
SODIUM BICARBONATESODIUM BICARBONATE8MDF5V39QOINJECTION, SOLUTION / INTRAVENOUS52 mgExact identifier — unii+dosage form
767 equally ranked IID candidates
SODIUM CHLORIDESODIUM CHLORIDE451W47IQ8XINJECTION, SOLUTION / SUBCUTANEOUS1486 mgExact identifier — unii+route+dosage form
382 equally ranked IID candidates
GLYCERINGLYCERINPDC6A3C0OXINJECTION, SOLUTION / SUBCUTANEOUS15 %w/vExact identifier — unii+route+dosage form
382 equally ranked IID candidates
SODIUM BICARBONATESODIUM BICARBONATE8MDF5V39QOINJECTION, SOLUTION / INTRAVENOUS52 mgExact identifier — unii+dosage form
767 equally ranked IID candidates
SODIUM BICARBONATESODIUM BICARBONATE8MDF5V39QOINJECTION, SOLUTION / INTRAVENOUS52 mgExact identifier — unii+dosage form
767 equally ranked IID candidates
GLYCERINGLYCERINPDC6A3C0OXINJECTION, SOLUTION / SUBCUTANEOUS15 %w/vExact identifier — unii+route+dosage form
382 equally ranked IID candidates
SODIUM CHLORIDESODIUM CHLORIDE451W47IQ8XINJECTION, SOLUTION / SUBCUTANEOUS1486 mgExact identifier — unii+route+dosage form
382 equally ranked IID candidates
SODIUM CHLORIDESODIUM CHLORIDE451W47IQ8XINJECTION, SOLUTION / SUBCUTANEOUS1486 mgExact identifier — unii+route+dosage form
382 equally ranked IID candidates
SODIUM CHLORIDESODIUM CHLORIDE451W47IQ8XINJECTION, SOLUTION / SUBCUTANEOUS1486 mgExact identifier — unii+route+dosage form
382 equally ranked IID candidates
SODIUM BICARBONATESODIUM BICARBONATE8MDF5V39QOINJECTION / SUBCUTANEOUSADJ PHExact identifier — unii+route
767 equally ranked IID candidates
PHENOLPHENOL339NCG44TVINJECTION, SOLUTION / SUBCUTANEOUS0.55 %w/vExact identifier — unii+route+dosage form
382 equally ranked IID candidates
SODIUM BICARBONATESODIUM BICARBONATE8MDF5V39QOINJECTION / SUBCUTANEOUSADJ PHExact identifier — unii+route
767 equally ranked IID candidates
SODIUM BICARBONATESODIUM BICARBONATE8MDF5V39QOINJECTION / SUBCUTANEOUSADJ PHExact identifier — unii+route
767 equally ranked IID candidates
SODIUM CHLORIDESODIUM CHLORIDE451W47IQ8XINJECTION, SOLUTION / SUBCUTANEOUS1486 mgExact identifier — unii+route+dosage form
382 equally ranked IID candidates
SODIUM BICARBONATESODIUM BICARBONATE8MDF5V39QOINJECTION / SUBCUTANEOUSADJ PHExact identifier — unii+route
767 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IINJECTION, SOLUTION / SUBCUTANEOUS1 %w/vExact identifier — unii+route+dosage form
382 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IINJECTION, SOLUTION / SUBCUTANEOUS1 %w/vExact identifier — unii+route+dosage form
382 equally ranked IID candidates
SODIUM BICARBONATESODIUM BICARBONATE8MDF5V39QOINJECTION, SOLUTION / INTRAVENOUS52 mgExact identifier — unii+dosage form
767 equally ranked IID candidates
SODIUM BICARBONATESODIUM BICARBONATE8MDF5V39QOINJECTION, SOLUTION / INTRAVENOUS52 mgExact identifier — unii+dosage form
767 equally ranked IID candidates
GLYCERINGLYCERINPDC6A3C0OXINJECTION, SOLUTION / SUBCUTANEOUS15 %w/vExact identifier — unii+route+dosage form
382 equally ranked IID candidates
SODIUM BICARBONATESODIUM BICARBONATE8MDF5V39QOINJECTION, SOLUTION / INTRAVENOUS52 mgExact identifier — unii+dosage form
767 equally ranked IID candidates
GLYCERINGLYCERINPDC6A3C0OXINJECTION, SOLUTION / SUBCUTANEOUS15 %w/vExact identifier — unii+route+dosage form
382 equally ranked IID candidates
SODIUM CHLORIDESODIUM CHLORIDE451W47IQ8XINJECTION, SOLUTION / SUBCUTANEOUS1486 mgExact identifier — unii+route+dosage form
382 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IINJECTION, SOLUTION / SUBCUTANEOUS1 %w/vExact identifier — unii+route+dosage form
382 equally ranked IID candidates
GLYCERINGLYCERINPDC6A3C0OXINJECTION, SOLUTION / SUBCUTANEOUS15 %w/vExact identifier — unii+route+dosage form
382 equally ranked IID candidates
HYDROCHLORIC ACIDHYDROCHLORIC ACIDQTT17582CBINJECTION, SOLUTION / SUBCUTANEOUS1037 mgExact identifier — unii+route+dosage form
382 equally ranked IID candidates
HYDROCHLORIC ACIDHYDROCHLORIC ACIDQTT17582CBINJECTION, SOLUTION / SUBCUTANEOUS1037 mgExact identifier — unii+route+dosage form
382 equally ranked IID candidates
PHENOLPHENOL339NCG44TVINJECTION, SOLUTION / SUBCUTANEOUS0.55 %w/vExact identifier — unii+route+dosage form
382 equally ranked IID candidates

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.